{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T16:47:12Z","timestamp":1792082832216,"version":"4.4.0"},"reference-count":50,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004252","name":"Qatar University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004252","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmn.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Pharmacology"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.coph.2021.08.015","type":"journal-article","created":{"date-parts":[[2021,9,23]],"date-time":"2021-09-23T21:53:40Z","timestamp":1632434020000},"page":"28-35","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["A computational overview on phylogenetic characterization, pathogenic mutations, and drug targets for Ebola virus disease"],"prefix":"10.1016","volume":"61","author":[{"given":"Karthick","family":"Vasudevan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Thirumal Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6639-3746","authenticated-orcid":false,"given":"S.","family":"Udhaya Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aisha","family":"Saleem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Nagasundaram","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Siva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Iftikhar Aslam","family":"Tayubi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5971-8290","authenticated-orcid":false,"given":"C.","family":"George Priya Doss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hatem","family":"Zayed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.coph.2021.08.015_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/s41572-020-0147-3","article-title":"Ebola virus disease","volume":"6","author":"Jacob","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.coph.2021.08.015_bib2","first-page":"39","article-title":"Ebola haemorrhagic fever virus: pathogenesis, immune responses, potential prevention","volume":"54","author":"Marcinkiewicz","year":"2014","journal-title":"Folia Med Cracov"},{"key":"10.1016\/j.coph.2021.08.015_bib3","series-title":"Ebola Virus Disease","year":"2020"},{"key":"10.1016\/j.coph.2021.08.015_bib4","series-title":"Ebola virus disease","year":"2021"},{"key":"10.1016\/j.coph.2021.08.015_bib5","series-title":"Situation Report #36 E: democratic Republic of the Congo (DRC) - ebola situation Report #36 - December 8, 2020 - Democratic Republic of the Congo","year":"2020"},{"key":"10.1016\/j.coph.2021.08.015_bib6","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1080\/21505594.2021.1898169","article-title":"Pathogenicity and virulence of ebolaviruses with species-and variant-specificity","volume":"12","author":"Yamaoka","year":"2021","journal-title":"Virulence"},{"key":"10.1016\/j.coph.2021.08.015_bib7","first-page":"1","article-title":"Risk assessment of Ebola Reston virus in humans in the Philippines","volume":"10","author":"Pe\u00f1as","year":"2019","journal-title":"Wester. Pacif. Surveill. Resp. J.: WPSAR"},{"key":"10.1016\/j.coph.2021.08.015_sref8","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1056\/NEJMra1901594","article-title":"Ebola","volume":"382","author":"Feldmann","year":"2020","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.coph.2021.08.015_bib9","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1146\/annurev-pathol-052016-100506","article-title":"The pathogenesis of ebola virus disease","volume":"12","author":"Baseler","year":"2017","journal-title":"Annu Rev Pathol"},{"key":"10.1016\/j.coph.2021.08.015_bib10","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/nri.2016.138","article-title":"Immunobiology of ebola and lassa virus infections","volume":"17","author":"Prescott","year":"2017","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.coph.2021.08.015_bib11","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1007\/s40259-013-0046-1","article-title":"Emerging targets and novel approaches to Ebola virus prophylaxis and treatment","volume":"27","author":"Choi","year":"2013","journal-title":"BioDrugs"},{"key":"10.1016\/j.coph.2021.08.015_sref12","doi-asserted-by":"crossref","first-page":"E999","DOI":"10.3390\/v11110999","article-title":"The Roles of ebola virus soluble glycoprotein in Replication, pathogenesis, and countermeasure development","volume":"11","author":"Zhu","year":"2019","journal-title":"Viruses"},{"key":"10.1016\/j.coph.2021.08.015_bib13","doi-asserted-by":"crossref","first-page":"e00438","DOI":"10.1128\/JVI.00438-17","article-title":"Ebola virus delta peptide is a viroporin","volume":"91","author":"He","year":"2017","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.coph.2021.08.015_bib14","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1126\/science.aad6117","article-title":"Structural and molecular basis for Ebola virus neutralization by protective human antibodies","volume":"351","author":"Misasi","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.coph.2021.08.015_bib15","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S0140-6736(16)32621-6","article-title":"Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola \u00c7a Suffit!)","volume":"389","author":"Henao-Restrepo","year":"2017","journal-title":"Lancet"},{"key":"10.1016\/j.coph.2021.08.015_bib16","doi-asserted-by":"crossref","first-page":"S404","DOI":"10.1086\/520591","article-title":"Assessment of a vesicular stomatitis virus-based vaccine by use of the mouse model of Ebola virus hemorrhagic fever","volume":"196","author":"Jones","year":"2007","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.coph.2021.08.015_bib17","doi-asserted-by":"crossref","first-page":"S612","DOI":"10.1093\/infdis\/jiy285","article-title":"Development of clinical-stage human monoclonal antibodies that treat advanced ebola virus disease in nonhuman primates","volume":"218","author":"Pascal","year":"2018","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.coph.2021.08.015_bib18","doi-asserted-by":"crossref","first-page":"16128","DOI":"10.1038\/nmicrobiol.2016.128","article-title":"Structures of Ebola virus GP and sGP in complex with therapeutic antibodies","volume":"1","author":"Pallesen","year":"2016","journal-title":"Nat Microbiol"},{"key":"10.1016\/j.coph.2021.08.015_bib19","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/S0969-2126(03)00050-9","article-title":"The matrix protein VP40 from Ebola virus octamerizes into pore-like structures with specific RNA binding properties","volume":"11","author":"Gomis-R\u00fcth","year":"2003","journal-title":"Structure"},{"key":"10.1016\/j.coph.2021.08.015_bib20","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/s40249-016-0105-1","article-title":"Virtual screening of the inhibitors targeting at the viral protein 40 of Ebola virus","volume":"5","author":"Karthick","year":"2016","journal-title":"Infect Dis Poverty"},{"key":"10.1016\/j.coph.2021.08.015_bib21","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1007\/s12539-016-0149-8","article-title":"Herbal lead as ideal bioactive compounds against probable drug targets of ebola virus in comparison with known chemical analogue: a computational drug discovery perspective","volume":"9","author":"Setlur","year":"2017","journal-title":"Interdiscip Sci"},{"key":"10.1016\/j.coph.2021.08.015_bib22","doi-asserted-by":"crossref","first-page":"33099","DOI":"10.1074\/jbc.M203775200","article-title":"Phosphorylation of VP30 impairs ebola virus transcription\u2217","volume":"277","author":"Modrof","year":"2002","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.coph.2021.08.015_bib23","doi-asserted-by":"crossref","first-page":"22723","DOI":"10.1074\/jbc.M114.575050","article-title":"Role of protein phosphatase 1 in dephosphorylation of Ebola virus VP30 protein and its targeting for the inhibition of viral transcription","volume":"289","author":"Ilinykh","year":"2014","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.coph.2021.08.015_bib24","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1038\/nature17180","article-title":"Therapeutic efficacy of the small molecule GS-5734 against Ebola virus in rhesus monkeys","volume":"531","author":"Warren","year":"2016","journal-title":"Nature"},{"key":"10.1016\/j.coph.2021.08.015_bib25","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.antiviral.2017.12.021","article-title":"Efficacy of favipiravir (T-705) in non-human primates infected with Ebola virus or Marburg virus","volume":"151","author":"Bixler","year":"2018","journal-title":"Antivir Res"},{"key":"10.1016\/j.coph.2021.08.015_bib26","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1038\/nature13027","article-title":"Protection against filovirus diseases by a novel broad-spectrum nucleoside analogue BCX4430","volume":"508","author":"Warren","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.coph.2021.08.015_sref27","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.coviro.2019.03.001","article-title":"Current status of small molecule drug development for Ebola virus and other filoviruses","volume":"35","author":"Edwards","year":"2019","journal-title":"Curr Opin Virol"},{"key":"10.1016\/j.coph.2021.08.015_bib28","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.celrep.2015.03.034","article-title":"An intrinsically disordered peptide from ebola virus VP35 controls viral RNA synthesis by modulating nucleoprotein-RNA interactions","volume":"11","author":"Leung","year":"2015","journal-title":"Cell Rep"},{"key":"10.1016\/j.coph.2021.08.015_bib29","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1021\/acsinfecdis.6b00209","article-title":"A\u00a0sensitive in\u00a0vitro high-throughput screen to identify pan-filoviral Replication inhibitors targeting the VP35-NP interface","volume":"3","author":"Liu","year":"2017","journal-title":"ACS Infect Dis"},{"key":"10.1016\/j.coph.2021.08.015_bib30","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1515\/biolog-2017-0012","article-title":"Potential Ebola drug targets \u2013 filling the gap: a critical step forward towards the design and discovery of potential drugs","volume":"72","author":"Balmith","year":"2017","journal-title":"Biologia"},{"key":"10.1016\/j.coph.2021.08.015_bib31","doi-asserted-by":"crossref","first-page":"S957","DOI":"10.1093\/infdis\/jir326","article-title":"Ebola virus enters host cells by macropinocytosis and clathrin-mediated endocytosis","volume":"204","author":"Aleksandrowicz","year":"2011","journal-title":"J\u00a0Infect Dis"},{"key":"10.1016\/j.coph.2021.08.015_bib32","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1016\/j.antiviral.2015.01.011","article-title":"Protease inhibitors targeting coronavirus and filovirus entry","volume":"116","author":"Zhou","year":"2015","journal-title":"Antivir Res"},{"key":"10.1016\/j.coph.2021.08.015_bib33","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pntd.0005540","article-title":"The phosphatidylinositol-3-phosphate 5-kinase inhibitor apilimod blocks filoviral entry and infection","volume":"11","author":"Nelson","year":"2017","journal-title":"PLoS Neglected Trop Dis"},{"key":"10.1016\/j.coph.2021.08.015_bib34","doi-asserted-by":"crossref","first-page":"e60579","DOI":"10.1371\/journal.pone.0060579","article-title":"A\u00a0systematic screen of FDA-approved drugs for inhibitors of biological threat agents","volume":"8","author":"Madrid","year":"2013","journal-title":"PloS One"},{"key":"10.1016\/j.coph.2021.08.015_bib35","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.88333","article-title":"Mapping the clinical outcomes and genetic evolution of Ebola virus in Sierra Leone","volume":"2","author":"Li","year":"2017","journal-title":"JCI Insight"},{"key":"10.1016\/j.coph.2021.08.015_bib36","doi-asserted-by":"crossref","first-page":"e01098","DOI":"10.1128\/JVI.01098-18","article-title":"Naturally occurring single mutations in ebola virus observably impact infectivity","volume":"93","author":"Wong","year":"2019","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.coph.2021.08.015_bib37","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1016\/j.cell.2016.10.014","article-title":"Ebola virus glycoprotein with increased infectivity dominated the 2013-2016 epidemic","volume":"167","author":"Diehl","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.coph.2021.08.015_bib38","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/j.cell.2016.10.013","article-title":"Human adaptation of ebola virus during the West african outbreak","volume":"167","author":"Urbanowicz","year":"2016","journal-title":"Cell"},{"key":"10.1016\/j.coph.2021.08.015_bib39","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.chom.2017.02.002","article-title":"Biochemical basis for increased activity of ebola glycoprotein in the 2013-16 epidemic","volume":"21","author":"Wang","year":"2017","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.coph.2021.08.015_bib40","doi-asserted-by":"crossref","first-page":"e01913","DOI":"10.1128\/JVI.01913-16","article-title":"Functional characterization of adaptive mutations during the West african ebola virus outbreak","volume":"91","author":"Dietzel","year":"2017","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.coph.2021.08.015_bib41","doi-asserted-by":"crossref","first-page":"e00177","DOI":"10.1128\/JVI.00177-17","article-title":"A\u00a0polymorphism within the internal fusion loop of the ebola virus glycoprotein modulates host cell entry","volume":"91","author":"Hoffmann","year":"2017","journal-title":"J\u00a0Virol"},{"key":"10.1016\/j.coph.2021.08.015_bib42","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/nmicrobiol.2016.151","article-title":"Intra-host dynamics of Ebola virus during 2014","volume":"1","author":"Ni","year":"2016","journal-title":"Nat Microbiol"},{"key":"10.1016\/j.coph.2021.08.015_bib43","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1016\/j.celrep.2015.08.038","article-title":"Emergence of ebola virus escape variants in infected non-human primates treated with the MB-003 antibody cocktail","volume":"12","author":"Kugelman","year":"2015","journal-title":"Cell Rep"},{"key":"10.1016\/j.coph.2021.08.015_bib44","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.cell.2020.03.011","article-title":"A\u00a0vaccine against ebola virus","volume":"181","author":"Ollmann Saphire","year":"2020","journal-title":"Cell"},{"key":"10.1016\/j.coph.2021.08.015_bib45","article-title":"A\u00a0prophylactic multivalent vaccine against different filovirus species is immunogenic and provides protection from lethal infections with Ebolavirus and Marburgvirus species in non-human primates","volume":"13","author":"Callendret","year":"2018","journal-title":"PloS One"},{"key":"10.1016\/j.coph.2021.08.015_bib46","doi-asserted-by":"crossref","first-page":"2338","DOI":"10.1016\/S0140-6736(18)33011-3","article-title":"Randomised controlled trial begins for Ebola therapeutics","volume":"392","author":"Nakkazi","year":"2018","journal-title":"Lancet"},{"key":"10.1016\/j.coph.2021.08.015_bib47","series-title":"Notes for the record: consultation on monitored emergency use of unregistered and investigational Interventions(MEURI) for ebola virus disease","author":"Cox","year":"2018"},{"key":"10.1016\/j.coph.2021.08.015_sref48","doi-asserted-by":"crossref","first-page":"4","DOI":"10.7573\/dic.2020-4-14","article-title":"The journey of remdesivir: from Ebola to COVID-19","volume":"9","author":"Pardo","year":"2020","journal-title":"Drugs Context"},{"key":"10.1016\/j.coph.2021.08.015_bib49","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0243270","article-title":"The transcriptomic profiling of SARS-CoV-2 compared to SARS, MERS, EBOV, and H1N1","volume":"15","author":"Alsamman","year":"2020","journal-title":"PloS One"},{"key":"10.1016\/j.coph.2021.08.015_bib50","doi-asserted-by":"crossref","first-page":"e00639","DOI":"10.1128\/genomeA.00639-15","article-title":"Molecular characterization of the first Ebola virus isolated in Italy, from a health care worker repatriated from Sierra Leone","volume":"3","author":"Castilletti","year":"2015","journal-title":"Genome Announc"}],"container-title":["Current Opinion in Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489221001363?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1471489221001363?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,26]],"date-time":"2025-10-26T06:53:05Z","timestamp":1761461585000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1471489221001363"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":50,"alternative-id":["S1471489221001363"],"URL":"https:\/\/doi.org\/10.1016\/j.coph.2021.08.015","relation":{},"ISSN":["1471-4892"],"issn-type":[{"value":"1471-4892","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A computational overview on phylogenetic characterization, pathogenic mutations, and drug targets for Ebola virus disease","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.coph.2021.08.015","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}